Security
Rein Therapeutics, Inc. Common Stock · RNTX
RNTXNASDAQCommon stockCurrentCIK 1420565Updated Oct 6, 2026
Name history
Aileron Therapeutics, Inc. · through Dec 9, 2024AILERON THERAPEUTICS INC · through Mar 29, 2024
RNTX price & chart
Loading TradingView…
NASDAQ:RNTX on TradingView ↗About the company
We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications. Our lead product candidate is LTI-03, a peptide for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis that has demonstrated the ability in both preclinical studies and clinical trials to protect healthy lung epithelial cells and reduce pro-fibrotic signaling. Our second product candidate is LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion patients, an indication that has no approved drug treatment. In June 2024, we decided to temporarily delay clinical development of LTI-01 in an effort to focus our resources on clinical development of LTI-03 and …
In the news
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update ↗
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders News provided by Rein Therapeutics, Inc. Jun 24, 2025, 10:11 ET Share this article Share to X Share this article Share to X Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 2025 ↗
Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update News provided by Rein Therapeutics, Inc. May 15, 2025, 16:09 ET Share this article Share to X Share this article Share to X RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in i ↗
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
SCHEDULE 13G/A - filed by Lynwood Capital Management Inc. regarding Rein Therapeutics, Inc.
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 53,706,000Source | 104,217,000Source | 65,973,000Source | 57,479,000Source | 109,400,000Source | 26,288,000Source | 57,628,000Source | 99,192,000Source | 24,158,000Source | 62,190,000Source | 106,008,000Source | 22,007,000Source |
| Property, Plant and Equipment, NetUSD | 0Source | 1,000Source | — | 1,000Source | 2,000Source | — | 1,000Source | 6,000Source | 0Source | 1,000Source | 19,000Source | 70,000Source |
| GoodwillUSD | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 42,200,000Source | 79,200,000Source | 13,500,000Source | 42,200,000Source | 79,200,000Source | 13,500,000Source | 42,200,000Source | 79,200,000Source | 13,500,000Source | 42,200,000Source | 79,200,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,048,000Source | 17,652,000Source | 8,542,000Source | 5,722,000Source | 21,917,000Source | 4,445,000Source | 7,428,000Source | 12,042,000Source | 3,215,000Source | 12,865,000Source | 17,313,000Source | 5,194,000Source |
| Assets, CurrentUSD | 5,174,000Source | 18,684,000Source | 41,453,000Source | 6,602,000Source | 23,159,000Source | 5,453,000Source | 8,331,000Source | 12,764,000Source | 4,326,000Source | 13,657,000Source | 18,266,000Source | 21,873,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,126,000Source | 1,007,000Source | 806,000Source | 880,000Source | 1,217,000Source | 1,008,000Source | 903,000Source | 697,000Source | 1,111,000Source | 792,000Source | 882,000Source | 606,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | — | 40,000Source |
| Other Assets, NoncurrentUSD | 2,000Source | 2,000Source | 1,710,000Source | 2,346,000Source | 709,000Source | 1,005,000Source | 766,000Source | 892,000Source | 2,000Source | 2,000Source | 2,193,000Source | 24,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,516,000Source | 8,985,000Source | 10,769,000Source | 9,466,000Source | 8,379,000Source | 14,697,000Source | 7,749,000Source | 7,858,000Source | 7,240,000Source | 7,798,000Source | 7,711,000Source | 3,384,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 111,000Source | 108,000Source | 172,000Source | 109,000Source | 107,000Source | 114,000Source | 108,000Source | 103,000Source | 113,000Source | 108,000Source | 91,000Source | 91,000Source |
| Retained Earnings (Accumulated Deficit)USD | -369,304,000Source | -310,419,000Source | -413,484,000Source | -363,723,000Source | -304,572,000Source | -407,109,000Source | -356,901,000Source | -295,630,000Source | -401,271,000Source | -351,400,000Source | -288,517,000Source | -272,785,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -44,000Source | -26,000Source | -69,000Source | -44,000Source | -22,000Source | -62,000Source | -32,000Source | -63,000Source | -62,000Source | -18,000Source | -63,000Source | -48,000Source |
| Stockholders' Equity Attributable to ParentUSD | 46,190,000Source | 95,232,000Source | 55,204,000Source | 48,013,000Source | 101,021,000Source | 11,591,000Source | 49,879,000Source | 91,334,000Source | 16,918,000Source | 54,392,000Source | 6,887,000Source | 18,623,000Source |
| Additional Paid in Capital, Common StockUSD | 370,422,000Source | 360,564,000Source | 423,580,000Source | 366,644,000Source | 360,503,000Source | 373,643,000Source | 361,699,000Source | 340,340,000Source | 373,133,000Source | 360,697,000Source | 295,376,000Source | 291,365,000Source |
| Liabilities and EquityUSD | 53,706,000Source | 104,217,000Source | 65,973,000Source | 57,479,000Source | 109,400,000Source | 26,288,000Source | 57,628,000Source | 99,192,000Source | 24,158,000Source | 62,190,000Source | 106,008,000Source | 22,007,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 5,744,000Source | 5,659,000Source | 9,709,000Source | 7,694,000Source | 4,937,000Source | 13,637,000Source | 5,977,000Source | 4,532,000Source | 6,180,000Source | 5,749,000Source | 4,385,000Source | 3,384,000Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 48,000Source | 33,000Source |
| Accounts Payable, CurrentUSD | 4,123,000Source | 1,079,000Source | 4,466,000Source | 6,028,000Source | 782,000Source | 6,263,000Source | 1,149,000Source | 2,156,000Source | 3,976,000Source | 911,000Source | 1,190,000Source | 1,720,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,772,000Source | 3,326,000Source | 1,060,000Source | 1,772,000Source | 3,326,000Source | 1,060,000Source | 1,772,000Source | 3,326,000Source | 1,060,000Source | 1,772,000Source | 3,326,000Source | — |
| Other Liabilities, NoncurrentUSD | 0Source | — | — | 0Source | 116,000Source | — | 0Source | — | 0Source | 277,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 43,627,000Source | — | — | — | — | — | — | — | — | 21,242,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 1,060,000Source | 1,772,000Source | 3,326,000Source | 16,000Source |
| Short-term Investments | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -5,838,000Source | -5,501,000Source | -49,871,000Source | -62,883,000Source | -15,732,000Source | -27,329,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 0Source | 1,000Source | 63,000Source | 119,000Source | 169,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 156,000Source | 264,000Source | 2,224,000Source | 1,117,000Source | 1,190,000Source | 2,083,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,288,000Source | 238,000Source | 3,065,000Source | -279,000Source | -4,982,000Source | 510,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -712,000Source | -1,544,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,424,000Source | -6,175,000Source | -19,361,000Source | -22,291,000Source | -19,808,000Source | -24,865,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 0Source | 96,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 16,196,000Source | 26,459,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 4,654,000Source | 738,000Source | 9,755,000Source | 17,818,000Source | 15,794,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,230,000Source | -5,437,000Source | -9,650,000Source | -4,473,000Source | 12,119,000Source | 1,594,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | -44,000Source | 0Source | -63,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,447,000Source | 508,000Source | 164,000Source | 256,000Source | 156,000Source | 264,000Source | 2,224,000Source | 1,117,000Source | 1,190,000Source | 2,083,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | 43,627,000Source | — | — | — | — | — | — | 21,242,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 49,000Source | 169,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | -6,000Source | — |
| General and Administrative ExpenseUSD | — | — | 3,811,000Source | 2,349,000Source | 2,438,000Source | 2,579,000Source | 2,157,000Source | 2,555,000Source | 10,902,000Source | 13,864,000Source | 11,357,000Source | 9,680,000Source |
| GoodwillUSD | — | — | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | 6,330,000Source | — |
| Goodwill, Impairment LossUSD | — | — | — | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | 0Source | — | 0Source | 0Source | 28,700,000Source | 37,000,000Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -712,000Source | -1,544,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,581,000Source | -5,847,000Source | -6,375,000Source | -6,822,000Source | -5,838,000Source | -5,501,000Source | -49,871,000Source | -62,883,000Source | -15,732,000Source | -27,329,000Source |
| Operating ExpensesUSD | — | — | 5,492,000Source | 6,071,000Source | 6,076,000Source | 6,871,000Source | 5,230,000Source | 5,609,000Source | 50,631,000Source | 65,112,000Source | 16,276,000Source | 27,647,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -89,000Source | 224,000Source | -299,000Source | 49,000Source | -608,000Source | 108,000Source | 48,000Source | 685,000Source | 544,000Source | 318,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 354,000Source | 737,000Source | 1,819,000Source | 10,645,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 1,000Source | 4,000Source | 143,000Source | — | — |
| Equity Method Investment, Other than Temporary Impairment | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | — | — | -5,492,000Source | -6,071,000Source | -6,076,000Source | -6,871,000Source | -5,230,000Source | -5,609,000Source | -50,631,000Source | -65,112,000Source | -16,276,000Source | -27,647,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -89,000Source | 224,000Source | -299,000Source | 49,000Source | -608,000Source | 108,000Source | 48,000Source | 685,000Source | 544,000Source | 318,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -712,000Source | -1,544,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -5,581,000Source | -5,847,000Source | -6,375,000Source | -6,822,000Source | -5,838,000Source | -5,501,000Source | -49,871,000Source | -62,883,000Source | -15,732,000Source | -27,329,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.21Source | -0.27Source | -0.1Source | -0.28Source | -0.19Source | -0.25Source | -1.96Source | -3.51Source | -3.42Source | -6.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.21Source | -0.27Source | -0.1Source | -0.28Source | -0.19Source | -0.25Source | -1.96Source | -3.51Source | -3.42Source | -6.02Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 26,361,386Source | 21,663,089Source | 67,084,661Source | 24,187,536Source | 30,354,647Source | 21,915,891Source | 25,444,795Source | 17,938,899Source | 4,598,715Source | 4,539,318Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 26,361,386Source | 21,663,089Source | 67,084,661Source | 24,187,536Source | 30,354,647Source | 21,915,891Source | 25,444,795Source | 17,938,899Source | 4,598,715Source | 4,539,318Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 3,811,000Source | 2,349,000Source | 2,438,000Source | 2,579,000Source | 2,157,000Source | 2,555,000Source | 10,902,000Source | 13,864,000Source | 11,357,000Source | 9,680,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source | — |
| Operating ExpensesUSD | — | — | 5,492,000Source | 6,071,000Source | 6,076,000Source | 6,871,000Source | 5,230,000Source | 5,609,000Source | 50,631,000Source | 65,112,000Source | 16,276,000Source | 27,647,000Source |
| Research and Development ExpenseUSD | — | — | 1,681,000Source | 3,722,000Source | 3,638,000Source | 4,292,000Source | 3,073,000Source | 3,054,000Source | 11,029,000Source | 14,248,000Source | 3,991,000Source | 17,967,000Source |
Offerings
Registration 333-295390
Registration 333-290016
Filing attachments
d111215dex991.htm · 8-K · 2026-09-04
EX-99.1 2 d111215dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Harnessing fibrosis, unleashing life Science Deck| September 2026 Copyright © 2026 Rein Therapeutics Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Rein Therapeutics, Inc. (“Rein”, the “Company”, “we”, “our” or “us”) within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to: the expected bene…
Read attachment ↗tm2613660d1_ex99-1.htm · SCHEDULE 13G · 2026-05-08
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value $0.001 per share, of Rein Therapeutics, Inc., and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filing. In evidence thereof, the undersigned hereby exe…
Read attachment ↗d168655dex991.htm · 8-K · 2026-05-04
EX-99.1 4 d168655dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) - Rein Therapeutics, Inc. (“Rein” or the “Company”) (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million…
Read attachment ↗d80335dex41.htm · 8-K · 2026-01-16
Exhibit 4.1 UNSECURED PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN EXEMPTION THEREFROM UNDER THE ACT AND ANY APPLICABLE SECURITIES LAWS.…
Read attachment ↗d47241dex991.htm · 8-K · 2025-11-03
EX-99.1 2 d47241dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis FDA lifts clinical hold following review of Company’s Complete Response submission. Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites. ─────────────────────────────────────────────────────────────────────────────────────────────────── Early data suggests that LTI-03 may…
Read attachment ↗d11439dex991.htm · 8-K · 2025-10-09
EX-99.1 2 d11439dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial Trial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and promote repair AUSTIN, Texas, Oct. 9, 2025 (GLOBE NEWSWIRE) - Rein Therapeutics (“Rein”) (NASDAQ: RNTX),…
Read attachment ↗